Table of Contents Table of Contents
Previous Page  1381 / 1851 Next Page
Information
Show Menu
Previous Page 1381 / 1851 Next Page
Page Background

Axel Grothey No66c- bevacizumab trial

continuing Bev post progression

Criticized by Kopetz